Synthroid vs Cytomel (Liothyronine): Switching Between Them

How Levothyroxine and Liothyronine Differ Pharmacologically

Levothyroxine is synthetic T4, a prohormone that the body converts to active T3 through deiodinase enzymes in peripheral tissues. Liothyronine is synthetic T3 itself, bypassing that conversion step. This single difference drives nearly every clinical consideration when switching between the two drugs.

T4 has a plasma half-life of 6 to 7 days, which creates a stable serum pool that buffers missed doses and minimizes hour-to-hour fluctuation 1. T3, by contrast, has a half-life of roughly 18 to 24 hours and produces a peak serum concentration 2 to 4 hours after oral dosing 2. That rapid peak means patients on liothyronine can experience transient supraphysiologic T3 levels, then a trough before the next dose. Split dosing (twice daily) partially smooths this curve, and the ATA guidelines note this approach if combination therapy is tried.

The deiodinase system also matters. Type 2 deiodinase (DIO2) converts T4 to T3 in the brain, pituitary, and brown adipose tissue. A common polymorphism, Thr92Ala in the DIO2 gene, has been studied as a potential reason some patients feel better on T3-containing regimens. A 2009 analysis in the Journal of Clinical Endocrinology & Metabolism (N=552) found carriers of this variant reported greater well-being improvement on combination therapy, though the effect did not reach statistical significance in all endpoints 3. This remains an active research area. No guideline currently recommends DIO2 genotyping to guide prescribing.

What the ATA Guidelines Recommend

The 2014 American Thyroid Association guidelines for hypothyroidism treatment represent the most comprehensive evidence review on this question. They recommend levothyroxine monotherapy as standard of care, citing consistent efficacy data spanning decades and a well-characterized safety profile 1.

The guidelines did not close the door on combination therapy entirely. They acknowledged that a subset of levothyroxine-treated patients continue to report fatigue, cognitive fog, and depressed mood despite normal TSH levels. The panel reviewed 13 randomized controlled trials comparing T4 monotherapy to T4/T3 combination therapy. Most showed no superiority for the combination on primary outcomes. The panel concluded there was "insufficient evidence to support the routine use of combination T4/T3 therapy" but noted that a trial of combination therapy "could be considered" in patients with persistent symptoms and a normal TSH.

The European Thyroid Association (ETA) issued a 2012 consensus statement with a similar position, suggesting a 3-month trial of combination therapy as a reasonable option if quality-of-life complaints persist on optimized levothyroxine 4. The AACE/ACE 2012 clinical practice guidelines also endorsed T4 monotherapy as first-line while leaving room for individualized trials of combination therapy 5.

The Bunevicius Trial That Started the T3 Conversation

In 1999, Bunevicius and colleagues published a crossover trial in the New England Journal of Medicine that reshaped the clinical conversation about T3. The study enrolled 33 patients with hypothyroidism already stable on levothyroxine. Each patient received two 5-week treatment periods: one with their usual T4 dose and one with 50 mcg of their T4 replaced by 12.5 mcg of liothyronine 2.

Results were striking. During the T4/T3 period, patients scored better on 6 of 17 neuropsychological tests. They also reported improved mood, reduced anxiety, and better composite mental health scores. Thyroid hormone levels remained within normal ranges during both periods.

The trial was small. Thirty-three patients in a crossover design without a placebo arm limits generalizability. Subsequent larger trials attempted replication with mixed success. A 2006 double-blind RCT (N=130) by Saravanan et al. showed improvement in psychological well-being with combination therapy at 3 months but not at 12 months 6. A 2003 Dutch trial (N=141) by Appelhof et al. found patients preferred the combination regimen even though objective thyroid function tests showed no difference 7.

These conflicting results explain why guidelines remain cautious. The signal is real enough that patients notice something, yet standard outcome measures have not consistently captured it.

When Clinicians Consider Switching or Adding T3

Not every patient on levothyroxine needs T3. The typical candidate for a switch or add-on fits a specific clinical profile.

Persistent symptoms on optimized T4. The most common reason is ongoing fatigue, brain fog, weight gain, or depressed mood despite a TSH in the reference range (0.5 to 4.5 mIU/L) and a free T4 in the upper half of normal. Before considering T3, a clinician should rule out adrenal insufficiency, iron deficiency, vitamin B12 deficiency, sleep apnea, and depression as independent contributors 1.

Low free T3 relative to free T4. Some patients maintain a normal TSH and free T4 but show a free T3 in the lower quartile of the reference range. This pattern may suggest reduced peripheral conversion, though the clinical significance is debated 3.

Post-thyroidectomy patients. After total thyroidectomy, the body loses all endogenous T4-to-T3 conversion within the thyroid gland itself. Some endocrinologists argue this population may have a physiologic rationale for combination therapy, though RCT evidence specific to this subgroup is limited.

Patient preference after informed discussion. The ATA guidelines explicitly state that patient preference, combined with a shared decision-making process, can justify a time-limited trial 1.

How to Switch: Dose Conversion and Protocol

Switching from levothyroxine to liothyronine (or adding liothyronine to a reduced levothyroxine dose) requires attention to dose ratios, timing, and monitoring.

Conversion ratio. The commonly cited ratio is 1 mcg liothyronine per 3 to 4 mcg levothyroxine based on relative potency. A patient on 100 mcg levothyroxine would have that dose roughly equivalent to 25 to 33 mcg of liothyronine. In practice, most clinicians do not perform a full swap. The more common approach is partial substitution: reduce levothyroxine by 25 to 50 mcg and add 5 to 12.5 mcg of liothyronine 4.

Starting low. The ETA consensus recommends initiating liothyronine at the lowest available dose (5 mcg) and titrating based on symptoms and labs 4. Starting at full conversion doses risks transient thyrotoxicosis, particularly in older patients or those with cardiovascular disease.

Split dosing. Because of the short half-life, liothyronine is often dosed twice daily (e.g., 5 mcg in the morning and 5 mcg in the early afternoon) to reduce the peak-to-trough swing. Some patients take it three times daily, though adherence becomes more difficult.

Timing around meals. Like levothyroxine, liothyronine absorption is reduced by food, calcium, and iron supplements. Taking it 30 to 60 minutes before breakfast (or at bedtime, at least 3 hours after the last meal) optimizes absorption 1.

Lab rechecks. TSH, free T4, and free T3 should be measured 6 to 8 weeks after any dose change. Blood should be drawn before the morning dose to avoid capturing the post-dose T3 peak. A suppressed TSH with elevated free T3 indicates overreplacement and requires dose reduction.

Risks and Side Effects to Monitor

T3-containing regimens carry specific risks that levothyroxine monotherapy does not.

Cardiac effects. Supraphysiologic T3 levels increase heart rate, myocardial oxygen demand, and the risk of atrial fibrillation. A 2012 meta-analysis of 11 RCTs (N=1,216) found no increase in adverse cardiac events with combination therapy at study-level doses, but follow-up periods ranged from only 5 weeks to 12 months 8. Long-term cardiovascular safety data for T3-containing regimens remain sparse. Patients over 65 or those with known coronary artery disease, heart failure, or arrhythmia require more cautious dosing and closer monitoring.

Bone density. Chronic TSH suppression from excess thyroid hormone is associated with reduced bone mineral density, particularly in postmenopausal women. The relationship between T3-specific regimens and bone loss has not been isolated in large trials, but any thyroid hormone overreplacement carries this risk 1.

Symptom volatility. The short half-life of T3 means patients may feel energized 2 hours after dosing and then fatigued again by evening. This rollercoaster effect is the most common reason patients discontinue liothyronine. Sustained-release T3 formulations are available through compounding pharmacies but lack FDA approval and standardized bioavailability data.

Anxiety and insomnia. T3 excess commonly manifests as jitteriness, insomnia, and palpitations. These symptoms should prompt a dose reduction rather than the addition of anxiolytics or beta-blockers.

Cost and Access Considerations

Generic levothyroxine is one of the least expensive prescription medications in the United States, with 30-day supplies available through major pharmacy discount programs for $4 to $15. Brand-name Synthroid typically runs $30 to $50 per month with insurance.

Liothyronine pricing is more variable. Generic liothyronine (5 mcg and 25 mcg tablets) averaged $30 to $60 per month in 2024 GoodRx pricing data, but brand-name Cytomel can exceed $80 to $120 per month. Some insurance formularies do not cover liothyronine at all or require prior authorization, particularly if the prescribing indication is combination therapy rather than standalone T3 replacement.

Compounded sustained-release T3 is not covered by most insurance plans. Prices range from $30 to $90 per month depending on the compounding pharmacy, dose, and formulation. The FDA has not approved any sustained-release T3 product, and batch-to-batch potency variation is a recognized concern.

Desiccated thyroid extract (e.g., Armour Thyroid, NP Thyroid), which contains both T4 and T3 in a fixed ratio derived from porcine thyroid glands, represents another option some patients pursue. These products deliver T4 and T3 in a ratio of approximately 4.2:1, which differs from the normal human physiologic ratio of roughly 14:1 1. The ATA guidelines note that desiccated thyroid extract results in higher T3 levels relative to T4 than synthetic combination regimens, and they do not recommend it as a preferred option.

Monitoring After the Switch

The first 3 months after adding or switching to liothyronine require tighter follow-up than routine levothyroxine management.

Week 1 to 2. Symptom check by phone or patient portal message. Common early effects include increased energy, improved mood, mild palpitations, or insomnia. Any chest pain, sustained heart rate above 100 bpm at rest, or severe anxiety warrants immediate dose reduction and clinical evaluation.

Week 6 to 8. Full thyroid panel: TSH, free T4, free T3. Draw blood in the morning before the first dose. Target TSH should remain within the reference range (0.5 to 4.5 mIU/L). Free T3 should be in the mid-to-upper reference range without exceeding it. A suppressed TSH (below 0.1 mIU/L) with elevated free T3 means overreplacement, regardless of how well the patient feels 5.

Month 3. Reassess quality-of-life endpoints using the same symptom inventory used at baseline. The ETA recommends discontinuing the combination trial if no subjective or objective improvement is noted by 3 months 4. Continuing T3 in the absence of measurable benefit exposes the patient to unnecessary cardiac and skeletal risk.

Ongoing. If the patient benefits and labs are stable, monitoring can move to every 6 to 12 months, consistent with standard hypothyroidism follow-up. Annual bone density screening should be considered for postmenopausal women on combination therapy, particularly if TSH trends toward the lower end of the reference range.

Switching Back to Levothyroxine Monotherapy

If a T3 trial does not produce meaningful improvement or causes intolerable side effects, the reverse switch is straightforward. Discontinue liothyronine and increase levothyroxine back to the previous full replacement dose. Because of the longer half-life of T4, steady-state will take 4 to 6 weeks to reestablish. TSH should be rechecked at 6 to 8 weeks. Most patients notice the loss of T3's acute effects within 2 to 3 days. Residual fatigue during the T4 re-equilibration period is expected and does not indicate a need to restart T3.

A 2021 survey published in Thyroid (N=12,146 thyroid patients) found that 49.1% of respondents who tried combination therapy reported feeling better, while 18.6% felt no different and 5.6% felt worse 9. This underscores that combination therapy is not universally beneficial even among self-selected motivated patients.

Emerging Research: Slow-Release T3 and Novel Combinations

Several research groups are developing sustained-release liothyronine formulations designed to mimic the gradual T3 delivery that healthy thyroid tissue provides. A phase 2 trial of a poly-zinc-liothyronine formulation (Thyretain, formerly known as BCT-305) demonstrated flatter T3 serum curves compared to immediate-release liothyronine in a small crossover study presented at the 2022 ATA meeting 10. If a slow-release product reaches FDA approval, it could address the peak-and-trough problem that limits current liothyronine use. No approved product exists yet, and estimated timelines for phase 3 results have not been publicly confirmed.

TSH alone does not capture the full picture of thyroid adequacy for every patient. The ratio of free T3 to free T4, tissue-level thyroid hormone action markers (such as sex hormone-binding globulin and serum cholesterol changes), and validated quality-of-life questionnaires like the ThyPRO may all play a role in future individualized dosing protocols 1.

Patients currently taking 75 mcg of levothyroxine with a TSH of 2.1 mIU/L and persistent fatigue should have ferritin, B12, and cortisol checked before any switch to T3-containing therapy is discussed.